Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.2.7 (
heparinase
)
1,270
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Of the four known tissue inhibitors of metalloproteinases (TIMPs),
TIMP-3
is distinguished by its tighter binding to the extracellular matrix. The present results show that glycosaminoglycans such as heparin, heparan sulfate, chondroitin sulfates A, B, and C, and sulfated compounds such as suramin and pentosan efficiently extract
TIMP-3
from the postpartum rat uterus. Enzymatic treatment by
heparinase
III or chondroitinase ABC also releases
TIMP-3
, but neither one alone gives complete release. Confocal microscopy shows colocalization of heparan sulfate and
TIMP-3
in the endometrium subjacent to the lumen of the uterus. Immunostaining of
TIMP-3
is lost upon digestion of tissue sections with
heparinase
III and chondroitinase ABC. The N-terminal domain of human
TIMP-3
was expressed and found to bind to heparin with affinity similar to that of full-length mouse
TIMP-3
. The A and B beta-strands of the N-terminal domain of
TIMP-3
contain two potential heparin-binding sequences rich in lysine and arginine; these strands should form a double track on the outer surface of
TIMP-3
. Synthetic peptides corresponding to segments of these two strands compete for heparin in the DNase II binding assay.
TIMP-3
binding may be important for the cellular regulation of activity of the matrix metalloproteinases.
...
PMID:TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. 1090 Jan 94